BrightPath Biotherapeutics
2 clinical trials · Sponsor
◉ Watch BrightPath Biotherapeutics
| Record | Firm | Date |
|---|---|---|
| GRN-1201 With Pembrolizumab in Subjects With Metastatic PD-L1+ NSCLC (NCT03417882) | BrightPath Biotherapeutics | 2019-01-03 |
| Phase 1 Study of GRN-1201 in HLA-A*02 Subjects With Resected Melanoma (NCT02696356) | BrightPath Biotherapeutics | 2016-04-01 |
Track BrightPath Biotherapeutics automatically
Every clearance here is in the API, with alerts when new ones post.